Events
A descriptive paragraph that tells clients how good you are and proves that you are the best choice that they’ve made.
Yakumed Awarded as the Company of the Year
As Yakumed is celebrating its 10th anniversary, I am delighted to share with you the great news that Yakumed was awarded “Company of the Year” by Pharma Tech Outlook.
This is a testament to the world-class quality of our services and the stellar reputation we built in the sector as a reliable company and partner for success in the Japanese Pharma/Biotech market.
The World Leading Service Provider Highly Specialized in Pharmaceuticals and Orphan Drugs in Japan
The Japanese pharmaceutical market ranks as the world’s third largest and operates within a distinct regulatory, business and cultural ecosystem. Equipped with extensive experience in navigating the complex framework, Yakumed is exclusively committed to leading and supporting pharmaceutical, gene therapy and medical device companies to establish a strong foothold in the Japanese market. With a highly respected multidisciplinary team of experts, Yakumed provides a comprehensive package of services that covers all aspects related to Japanese market. It spans the entire development and life cycle stages of a pharmaceutical product. It is the only company in the world to offer such wide range of services dedicated to Japan.
“We are not a conventional service provider. We are a committed long-term partner, leading our Pharma/Biotech clientele to unlock the potential of the Japanese market, overcome the challenges and achieve commercial success in Japan,” says Dr. Mohamed Oubihi, President and CEO of Yakumed.
The firm has successfully supported 70 U.S. and European companies to develop, register and commercialize their pharmaceutical drugs in Japan. It provides a diverse range of services, including Japan’s entry strategy, market research, business development and partnering, clinical development, regulatory affairs, market access, chemistry, manufacturing, and controls (CMC), supply chain, pharmaceutical distribution, pharmacovigilance, marketing strategies and commercial launch.
We have proudly contributed to the development, approval and commercialization of numerous drugs which impact the lives of patients in Japan
Addressing Pharma Industry Challenges with Robust Strategies and Excellent Execution
Providing the highest level of service quality is Yakumed’s top priority. The time allocated to each product for Japan strategy, the meticulous attention to details when delivering services, and the sophisticated execution of intricate strategies contribute to the firm’s strategic and operational excellence.
Yakumed’s team comprises esteemed Japanese professionals with diverse subject-matter expertise. They are instrumental in providing world-class strategy advice and excellent operational support for the development, approval and commercialization of life-saving drugs in Japan.
“I am very proud of my team. Thanks to their deep insights, hard work and dedication we have built an excellent reputation,” states Dr. Oubihi.
The Real Impact is on the Lives of Patients
Yakumed has proudly contributed to the development and approval of numerous drugs which impact the lives of patients in Japan.
The firm led and supported numerous U.S. and European companies specialising in orphan diseases and cancer with their successful entry into the Japanese market. These long- term projects included -among others- the evaluation of market commercial potential (market research), KOL selection and interaction, clinical development and regulatory (PMDA consultations), Regulatory filing ( Japan NDA), Orphan Drug Designation, Distribution and 3PL strategy and set up, Supply Chain preparations, establishment of a representative affiliate in and product launch in Japan. Currently, these multinational companies have accomplished sales of over $100 million in Japan.
World-Leader in Regulatory, Development and Commercialization of Orphan Drugs in Japan
Yakumed offers a unique platform for strategic and operational aspects in regulatory, development and commercialization of pharmaceutical drugs and medical devices in Japan. The only one in the World in term of its breadth and coverage.
As MHLW is introducing new reforms which include the development and registration of Orphan Drugs, there are great opportunities in the future for orphan drugs and new technologies in Japan.
Dr Oubihi concludes “Yakumed has built a stellar reputation as a reliable company and partner for the development and commercialization of orphan drugs in Japan. We are very excited about the future! We will build on our strong legacy to carry on with our mission of introducing novel drugs to improve the health of patients in Japan”.
Events
Gene and Cell Therapy World Congress
The president and CEO of Yakumed Dr. Mohamed Oubihi was invited at the World Congress for Cell and Gene Therapy in London From our perspective as a company specialized in the Japanese Pharma/Gene therapy market, Yakumed will be delighted to share its views and experiences with players in this exciting field!
Events
The International eHealth Forum in Morocco
The president and CEO of Yakumed Dr. Mohamed Oubihi was invited to speak at the international eHealth Forum in Rabat about Digital Health in Japan!
Events
Yakumed attend the 20th Annual DIA meeting in Tokyo
Yakumed team has been very active in the DIA meeting in Tokyo this week. It was great to have fruitful discussions with PMDA and MHLW about the upcoming regulatory changes in Japan and their impact on drug development and access.
Events
Yakumed attend Showcase Biotech SF Jan 2024
Yakumed team is excited to attend Biotech Showcase 2024, January 8–10, 2024 in San Francisco.
Events
Meeting in Tokyo 2023
Here in Tokyo with several members of the regulatory team, we had fruitful discussions about our journey in supporting numerous companies in the rare disease space. We touched also on the recently introduced incentives by MHLW to expedite the development and registration of orphan drugs in Japan. Very proud of our achievements in supporting PMDA consultation, development, approval and commercialization of numerous orphan drugs in Japan.
Events
Company of the Year
As Yakumed is celebrating its 10th anniversary, I am delighted to share with you the great news that Yakumed was awarded "Company of the Year" by Pharma Tech Outlook. This is a testament to the world-class quality of our services and the stellar reputation we built in the sector as a reliable company and partner for success in the Japanese Pharma/Biotech market.